Clinton Foundation Partnered With Chinese Pharma

225

The Clinton Foundation partnered with a Chinese pharmaceutical company, underscoring the relationship between American Democrat elites and the Chinese. President Donald Trump has teased an executive order to stifle the monopoly Chinese drugmakers have on the American pharmaceutical market, which is a dire situation considering that China is engaged in a cold war against the United States. While globalist billionaire Michael Bloomberg built a business empire hand-in-hand with the Chinese Communists, the Clintons also have close Chinese ties that contributed to China’s upper hand in our tense international relationship. The Clinton Foundation received a $2 million pledge in 2013 from Rilin Enterprises, a Chinese company owned by a Chinese parliament member.

Philanthropy News Digest reported in 2005:

“The Clinton Foundation in Little Rock, Arkansas has announced a deal with Mchem Pharma Group of Xiamen, China, to supply discounted chemical ingredients to producers of generic AIDS antiviral drugs in India and Africa, the Wall Street Journal reports.

According to the foundation, Mchem will supply pharmaceutical intermediates and active pharmaceutical ingredients to drug manufacturers, including Aspen Pharmacare Holdings Ltd. in South Africa, and Cipla, Hetero Drugs Ltd., Matrix Laboratories, and Ranbaxy Laboratories in India. The move is designed to ensure that the growing number of new AIDS drugs on the market reach HIV/AIDS patients in the developing world. Mchem’s output, for example, initially will be enough to treat about 400,000 patients a year.

The agreement makes Mchem the first Chinese company to join the expanding network of partners enlisted by the Clinton Foundation, which has brokered deep discounts in AIDS drugs and diagnostics since 2003. In February, the foundation announced an agreement with China’s Ministry of Health to deliver treatment to two hundred children with HIV/AIDS.

“Mchem is one of China’s leading suppliers of the pharmaceutical products that make treatment of HIV/AIDS possible,” said Ira C. Magaziner, chairman of the Clinton Foundation HIV/AIDS Initiative. “I applaud Mchem’s commitment to increase supply of high-quality HIV/AIDS pharmaceuticals at affordable prices. As access to treatment continues to expand, Mchem and other leading pharmaceutical companies in China will play an increasingly important role.”

Philanthropy News Digest passage ends

The Clinton Foundation also gave a key assist to Chinese vaccine makers.

Investment Watch Blog reported:

Because of a recent classification change, Chinese manufactured vaccines have been given the greenlight to be shipped in bulk to as many as 152 low and middle-income countries and can now bypass any inspection from any other country, including the U.S. — all because of the work of the Clinton Foundation.

The World Health Organization (WHO) has reported that vaccines will be pre-qualified, meaning they are so “confident in the quality, safety and effectiveness of vaccines that are made in China” that other countries will no longer test them for safety.

The Clinton Foundation, which is heavily involved in vaccine programs across the world, has reportedly been working with the Chinese vaccine manufacturers to give them pre-qualification, which was achieved in 2014 with little mention by the mainstream media.

A report by WHO states: “The Clinton Health Access Initiative (CHAI) has been working with Chinese suppliers to support their applications for WHO prequalification for several vaccine candidates for the last two years, says Joshua Chu, CHAI’s Director, Vaccines Markets.”

Investment Watch Blog passage ends

Welcome to the Wide World of Globalism.